Compare Neurocrine Biosciences Inc (NBIX) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Schwab US Dividend Equity ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Schwab US Dividend Equity ETF trades at $32.82. Which is the better fit depends on your goals.
| NBIX | SCHD | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $180.55 | $33.04 |
52-Week Low | $123.10 | $26.38 |
Enterprise Value | $16.49B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
